Zacks Investment Research on MSN3d
IONS Out-Licenses ex-U.S. Rights for Rare Disease Drug Tryngolza to SobiIonis Pharmaceuticals IONS signed a license agreement with Sweden-based Sobi. Per the terms, Sobi will acquire exclusive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback